We have created a new pharmaceutical business, Propella Therapeutics, Inc. Propella Therapeutics develops innovative, best-in-class prescription therapeutics with an eye toward accelerated approvals with mitigated risk.
Propella Therapeutics uses proven science to produce products that are safer and more effective (i.e., smarter). Its drug candidates include: (1) CGS-200-5, a phase 3-ready product for the treatment of osteoarthritis pain, (2) PRL-01, a clinical candidate for the treatment of herpes labialis, and (3) PRL-02, a clinical candidate for the treatment of metastatic prostate cancer.
Vizuri Health Sciences Consumer Healthcare, Inc. (a.k.a. VHS Consumer Healthcare) has been formed to guide the growth and rapid expansion of its innovative products within the PainBloc24® brand of over-the-counter topical analgesics and other pain management solutions. With major distribution across more than 25,000 retail stores, and a growing e-commerce business, our brand is resonating with consumers and providing them with leading-edge solutions for delivering pain relief.
